FDA approves Dupixent (dupilumab) for children with eosinophilic esophagitis

The U.S. Food and Drug Administration has approved Regeneron’s Dupixent (dupilumab) for the treatment of pediatric patients (aged one to 11 years) with eosinophilic esophagitis (EoE).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup